Mizuho raised the firm’s price target on Cytokinetics (CYTK) to $100 from $84 and keeps an Outperform rating on the shares. The bullish case is supported by extending aficamten IP to 2041, with the ACACIA-HCM Phase 3 study poised to generate one of the year’s largest clinical datasets in biotech, the analyst tells investors in a research note. Sentiment appears receptive, with potential for the stock to revisit $90-$100+ if the trial succeeds, keeping the outlook constructive, Mizuho adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- JPMorgan ups Cytokinetics target, adds to Analyst Focus List
- Cytokinetics announces four presentations in obstructive HCM at ACC Expo
- Cytokinetics price target raised to $69 from $61 at UBS
- Cytokinetics Earnings Call Marks High-Stakes Launch Phase
- FDA Disruptions and Budget Cuts Pose Rising Regulatory Risk to Cytokinetics’ Drug Pipeline